Kiwi Biosciences Scores $1.5M Funding Boost to Launch FODZYME: A New Era for IBS Relief and Enjoyable Meals

Kiwi Biosciences is excited to announce a major milestone in its mission to improve the quality of life for the 40 million Americans living with Irritable Bowel Syndrome (IBS). The innovative biotechnological company has raised $1,500,000 in its latest round of funding, demonstrating strong investor confidence in its groundbreaking approach to digestive health. Kiwi Bio is at the forefront of enzyme development, with a pioneering portfolio that focuses on creating solutions to alleviate the dietary limitations often faced by those with IBS. The company’s first patent-pending product, FODZYME, represents a world-first in digestive enzyme technology by actively breaking down common dietary triggers found in foods like garlic, onion, wheat, and banana. This novel formula is designed to reduce the gas, bloating, and discomfort that many IBS sufferers experience, thereby allowing them to enjoy their favorite foods without the fear of unpleasant symptoms. The newly secured funds will be used to further refine and scale FODZYME, propelling it through critical stages of testing and commercial production. This investment not only supports technological advancement and regulatory development but also reinforces Kiwi Biosciences’ commitment to meeting an urgent, unmet need in the marketplace. As the company continues to innovate and lead the conversation on gut health, this funding round marks a significant step toward transforming the lives of individuals burdened by digestive disorders. With ongoing support from investors and the scientific community, Kiwi Biosciences is poised to set new benchmarks in how we treat and manage IBS, giving hope to millions for a future where food is synonymous with enjoyment rather than discomfort.